These enrichment-based next-generation sequencing (NGS) reagents enable simultaneous analysis of DNA and RNA, and can cover a wide range of cancer variant types. This methodology provides laboratories with a deep view into the genetics of cancer.
- Accurate Results from Low-Quality Samples1
Enables variant detection with as little as 40 ng DNA and RNA input, maximizing the results from precious formalin-fixed, paraffin-embedded (FFPE) samples.
- Supports Comprehensive Coverage of Cancer-Related Variants
Allows the assessment of multiple variant types in one assay using DNA and RNA which creates efficiencies in sample usage, time, and cost.